Glider | $4,000,000 | (Apr 18, 2025)
Graze Social | $1,000,000 | (Apr 18, 2025)
Nyobolt | $30,000,000 | (Apr 18, 2025)
Certified by Founder
Lodge
Exeliom Biosciences
start up
France
- Dijon, Bourgogne-Franche-Comté
- 21/07/2023
- Series A
- $8,898,320
At Exeliom Biosciences, we develop single bacterial strain drug candidates to deliver first-in-class microbiome-based therapeutics (also known as Live Biotherapeutics) for the treatment of immune-mediated diseases, with specific focus on inflammatory bowel diseases (IBD), and Crohn’s Disease as a first indication
- Industry Pharmaceutical Manufacturing
- Website https://www.exeliombio.com/
- LinkedIn https://www.linkedin.com/company/nextbiotix/
Related People
Benjamin HadidaFounder
France -
Paris, Île-de-France
Biotech company builder and new therapeutic class explorer
Booked it | $3,316,375 | (Apr 18, 2025)
FOTENIX | $2,785,755 | (Apr 18, 2025)
Exaforce Inc. | $75,000,000 | (Apr 18, 2025)
Pillar Security | $9,000,000 | (Apr 18, 2025)
Cy4Data Labs | $10,000,000 | (Apr 18, 2025)
Meadow | $14,000,000 | (Apr 18, 2025)
Trellis Health | $1,800,000 | (Apr 18, 2025)
RISA | $3,500,000 | (Apr 18, 2025)
Vizzy | B Corp™ | $4,841,908 | (Apr 18, 2025)
Assort Health | $26,000,000 | (Apr 18, 2025)